汇宇制药跌5.24% 上市即巅峰募24.7亿中信建投保荐

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) is currently experiencing a decline in stock price, closing at 20.60 yuan with a drop of 5.24%, indicating a state of being below its initial public offering (IPO) price [1] Group 1: IPO Details - Huiyu Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with a public offering of 63.6 million shares at an issue price of 38.87 yuan per share [1] - The stock reached an intraday high of 42.59 yuan on its listing day, marking the highest price since its IPO [1] - The total funds raised from the IPO amounted to 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, exceeding the original plan by 453 million yuan [1] Group 2: Fund Allocation - The funds raised are intended for three main projects: the second phase of the EU-standard injectable drug industrialization base, the establishment of the Huiyu Innovative Drug Research Institute, and to supplement working capital [1] - The total issuance costs were 111 million yuan, with underwriting fees to CITIC Securities and Guodu Securities amounting to 98.875 million yuan [1]